Literature DB >> 9367395

Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation.

S M McHugh1, T L Rowland.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9367395      PMCID： PMC2265499          DOI： 10.1111/j.1365-2249.1997.tb08310.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  46 in total

1.  Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, Staphylococcal enterotoxin A, and purified protein derivative.

Authors:  E J Shannon; F Sandoval
Journal:  Immunopharmacology       Date:  1995-11

2.  Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production.

Authors:  B E Turk; H Jiang; J O Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

3.  Potent inhibition of tumor necrosis factor-alpha production by tetrafluorothalidomide and tetrafluorophthalimides.

Authors:  S Niwayama; B E Turk; J O Liu
Journal:  J Med Chem       Date:  1996-08-02       Impact factor: 7.446

4.  Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity.

Authors:  G W Muller; L G Corral; M G Shire; H Wang; A Moreira; G Kaplan; D I Stirling
Journal:  J Med Chem       Date:  1996-08-16       Impact factor: 7.446

5.  New roles for thalidomide.

Authors:  R J Powell
Journal:  BMJ       Date:  1996-08-17

6.  Inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production.

Authors:  H Miyachi; A Azuma; E Hioki; S Iwasaki; Y Kobayashi; Y Hashimoto
Journal:  Biochem Biophys Res Commun       Date:  1996-07-16       Impact factor: 3.575

7.  Cell type-/inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production and its enantio-dependence.

Authors:  H Miyachi; A Azuma; E Hioki; S Iwasaki; Y Kobayashi; Y Hashimoto
Journal:  Biochem Biophys Res Commun       Date:  1996-09-13       Impact factor: 3.575

8.  Tumor necrosis factor alpha gene regulation in activated T cells involves ATF-2/Jun and NFATp.

Authors:  E Y Tsai; J Jain; P A Pesavento; A Rao; A E Goldfeld
Journal:  Mol Cell Biol       Date:  1996-02       Impact factor: 4.272

9.  A tumor necrosis factor (TNF) receptor fragment attenuates TNF-alpha- and muramyl dipeptide-induced sleep and fever in rabbits.

Authors:  S Takahashi; L Kapás; J M Krueger
Journal:  J Sleep Res       Date:  1996-06       Impact factor: 3.981

10.  The effect of thalidomide on BCG-induced granulomas in mice.

Authors:  F M Aarestrup; S C Gonçalves-da-Costa; E N Sarno
Journal:  Braz J Med Biol Res       Date:  1995-10       Impact factor: 2.590
View more
  9 in total

Review 1.  Anti-TNF antibody treatment of Crohn's disease.

Authors:  S J van Deventer
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Transport of thalidomide by the human intestinal caco-2 monolayers.

Authors:  Shufeng Zhou; Yan Li; Phillip Kestell; Peter Schafer; Eli Chan; James W Paxton
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jan-Jun       Impact factor: 2.441

Review 3.  Thalidomide in gastrointestinal disorders.

Authors:  A Bousvaros; B Mueller
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Thalidomide analogue CC-3052 reduces HIV+ neutrophil apoptosis in vitro.

Authors:  M Guckian; I Dransfield; P Hay; A G Dalgleish
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

5.  The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study.

Authors:  Sriram Yennurajalingam; Jie S Willey; J Lynn Palmer; Julio Allo; Egidio Del Fabbro; Evan N Cohen; Sanda Tin; James M Reuben; Eduardo Bruera
Journal:  J Palliat Med       Date:  2012-08-10       Impact factor: 2.947

6.  Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration.

Authors:  Matthew Hoffmann; Gondi Kumar; Peter Schafer; Dorota Cedzik; Lori Capone; Kei-Lai Fong; Zheming Gu; Dennis Heller; Hao Feng; Sekhar Surapaneni; Oscar Laskin; Anfan Wu
Journal:  Xenobiotica       Date:  2011-08-23       Impact factor: 1.908

7.  Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration.

Authors:  Matthew Hoffmann; Claudia Kasserra; Josephine Reyes; Peter Schafer; Jolanta Kosek; Lori Capone; Anastasia Parton; Heasook Kim-Kang; Sekhar Surapaneni; Gondi Kumar
Journal:  Cancer Chemother Pharmacol       Date:  2012-12-01       Impact factor: 3.333

8.  Thalidomide treatment in cutaneous lesions of systemic lupus erythematosus: a multicenter study in China.

Authors:  Dandan Wang; Haifeng Chen; Shiying Wang; Yaohong Zou; Jing Li; Jieping Pan; Xiangdang Wang; Tianli Ren; Yu Zhang; Zhiwei Chen; Xuebing Feng; Lingyun Sun
Journal:  Clin Rheumatol       Date:  2016-04-21       Impact factor: 3.650

Review 9.  A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo Nodularis.

Authors:  Victoria M Lim; Eric L Maranda; Vivek Patel; Brian J Simmons; Joaquin J Jimenez
Journal:  Dermatol Ther (Heidelb)       Date:  2016-06-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.